Lumida
/LUNG
⌘K
Pulmonx Corp

Pulmonx Corp

LUNG
$1.85USD+0.00%+0.00 today

MARKET CAP

79.5M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
TrimMedium

In a Stage 4 decline featuring persistent lower highs and lower lows, the medium-term bias remains bearish under declining EMAs and distribution volume. Short-term timing is neutral as price tightly tracks flat EMAs and is oversold, suggesting risk of a bounce. Therefore, execution is deferred with a Trim approach, awaiting stalled rallies into structural resistance.

  • FY26 revenue guided at $90–92 M supports growth outlook
  • Q2 adjusted EBITDA loss fell to $5.1 M from $8.4 M YoY
  • Q2 revenue declined to $22.8 M due to China distributor gap
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$48.4M$53.7M$68.7M$83.8M$90.5M
YoY %+47.9%+10.8%+28.0%+22.0%+8.0%
P / Sales23.9x5.2x7.0x3.2x1.0x
EV / Sales21.7x4.0x6.7x3.2x1.1x
Gross Profit, Adj.$35.6M$39.9M$50.8M$62.0M$67.1M
YoY %+68.1%+11.9%+27.3%+22.2%+8.3%
Margin %73.6%74.3%73.9%74.0%74.2%
EV / Gross Profit29.5x5.4x9.0x4.4x1.4x
EBITDA, Adj.$-46.4M$-54.6M$-60.4M$-56.2M$-52.6M
YoY %-45.8%-17.6%-10.5%+6.9%+6.4%
Margin %-95.9%-101.8%-87.9%-67.1%-58.1%
EV / EBITDA-22.7x-4.0x-7.6x-4.8x-1.8x
EBIT$-47.3M$-58.6M$-61.9M$-57.7M$-53.7M
YoY %-46.3%-24.0%-5.6%+6.8%+7.0%
Margin %-97.7%-109.3%-90.2%-68.9%-59.3%
EV / EBIT-22.2x-3.7x-7.4x-4.7x-1.8x
Net Income$-48.7M$-58.9M$-60.8M$-56.4M$-54.0M
YoY %-51.0%-21.1%-3.3%+7.3%+4.2%
Net Margin-100.5%-109.8%-88.6%-67.3%-59.7%
EPS (GAAP)-$1.35-$1.59-$1.60-$1.44-$1.33
YoY %+57.3%-17.8%-0.6%+10.0%+7.6%